High-dose treatment with autologous stem cell transplantation versus sequential chemotherapy: the GELA experience.
Autologous stem-cell transplantation (ASCT) has permitted to deliver high-dose therapy (HDT). In aggressive lymphomas, the GELA group conducted prospective and retrospective studies comparing HDT + ASCT to conventional sequential chemotherapy. In relapsing patients and in partial remission, retrospective studies showed a survival advantage for HDT + ASCT over sequential chemotherapy. In complete response, advantage for HDT + ASCT was demonstrated in a prospective trial only for patients with high intermediate or high risk in the IPI score. The attainment of a maximal reduction of the tumoral mass before going HDT is very important either in first line or in relapsing patients.
Bosly
A
A
Mont-Godinne University Hospital, Yvoir, Belgium. andre.bosly@sang.ucl.ac.be
Haioun
C
C
Gisselbrecht
C
C
Reyes
F
F
Coiffier
B
B
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000592:standards; D003131:Combined Modality Therapy; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D012074:Remission Induction / Q000379:methods; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents